Avalo Therapeutics (AVTX) Change in Accured Expenses (2014 - 2026)

Avalo Therapeutics' Change in Accured Expenses history runs 13 years deep, the most recent figure standing at -$1.5 million for Q1 2026.

• Quarterly Change in Accured Expenses rose 12.06% year-over-year to -$1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (up 692.49% YoY) and the FY2025 annual result came in at $6.7 million, up 699.64% from the prior year.
• Change in Accured Expenses was -$1.5 million for Q1 2026 at Avalo Therapeutics, down from $5.4 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $5.4 million in Q4 2025 and bottomed at -$4.9 million in Q1 2023.
• A 5-year average of -$507294.1 and a median of -$856000.0 in 2024 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses plunged 726.21% — and 2025, when it surged 435.54%.
• Avalo Therapeutics' Change in Accured Expenses stood at -$488000.0 in 2022, then tumbled by 96.72% to -$960000.0 in 2023, then surged by 204.06% to $999000.0 in 2024, then jumped by 435.54% to $5.4 million in 2025, then slumped by 127.94% to -$1.5 million in 2026.
• Business Quant data shows AVTX's Change in Accured Expenses at -$1.5 million in Q1 2026, $5.4 million in Q4 2025, and $1.0 million in Q3 2025.